EUCTR2008-006787-11-GB进行中（未招募）不适用
A randomized, double blind, placebo-controlled, 2-period cross over study to evaluate effects of S-555739 on prostaglandin D2 (PGD2) induced nasal airway resistance in healthy adult volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Subjects must meet all of the following criteria to be included in the study.
- •1. Those who understand the procedures of the study and agree to participate in the study by providing written informed consent.
- •2. Male between 18 and 55 years of age at screening.
- •3. Those with a body mass index (BMI) of =18.0 to <29 kg/m2.
- •4. Those judged to be in generally good health and with no clinically significant findings on the basis of the medical history, physical examination and laboratory evaluation.
- •5. Those who have positive responses to PGD2 induced NAR (PD75 =32 µg) at the screening visit.
- •6. Provide written (signed) informed consent to participate in the trial prior to any trial specific screening procedures, with the understanding that the subject has the right to withdraw from the trial at any time, without prejudice.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet any of the following criteria must be excluded from the study.
- •1. Current or recent past abusers of alcohol (alcohol consumption > 40 grams / day), or those with a positive alcohol breath test at screening or current users or recent past abuser of illicit drugs (amphetamines, benzodiazepines, barbiturates, cannabis, cocaine, opiates).
- •2. Smokers within 6 months before the study.
- •3. Those who have participated in a clinical trial involving an investigational or marketed drug within 4 weeks of screening.
- •4. Those in a situation or any condition which, in the opinion of the investigator, may interfere with optimal participation in the study.
- •5. Those not willing to discontinue grapefruit whole or juice consumption during the study.
- •6. Those with active allergic rhinitis within 3 weeks prior to randomisation.
- •7. Those with perennial allergic rhinitis history who present current symptoms or within 3 weeks prior to randomisation.
- •8. Those receiving medications for allergic rhinitis and/or asthma within 3 weeks prior randomisation..
- •9. Those with an upper respiratory tract infection (URI), sinusitis, infectious rhinitis, ocular infection, or history of any of these within 3 weeks prior to the randomisation.
- •10. Those unable to tolerate the active posterior rhinomanometry and / or acoustic rhinometry procedures.
- •11. Those with a baseline total NAR >0.4 Pa/cm3/s.
- •12. Those who respond to intranasal control solution provocation with a >30% increase in total NAR.
- •13. Those who have undergone major surgical (requiring general anaesthetic) procedures or procedures to the nasopharynx within 4 weeks of randomisation.
- •14. Those with a history of an anaphylactic allergic reaction related to food or administration of either a marketed or investigational drug.
- •15. Those currently using any prescription or non-prescription drugs on a regular basis or within 2 weeks prior to randomisation.
- •16. Those who have received immunotherapy within 6 months of randomisation.
- •17. Those who have donated 400 mL of blood within 12 weeks before randomisation or 200 mL or more, within the 4 weeks before randomisation or any amount from screening to first visit.
研究者
相似试验
已完成
不适用
A randomized, double blind, placebo-controlled, 2-way cross-over study to investigate the effects of inhaled THC on resting state functional magnetic resonance imaging in healthy volunteersNL-OMON32445Centre for Human Drug Research12
进行中（未招募）
1 期
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsType 2 Diabetes mellitusMedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-003292-19-GBSanofi-Aventis Recherche & Développement350
进行中（未招募）
1 期
A clinical study comparing efficacy and safety of xevinapant against placebo when given with radiotherapy in participants who had their locally advanced squamous cell carcinoma of the head and neck removed by surgery, are at high risk for the cancer to return and who cannot be treated with high-dose cisplatin.Resected squamous cell carcinoma of the head and neckMedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001144-18-NLMerck Healthcare KGaA700
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone. - GETGOAL-PType II diabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005884-92-ATSanofi-Aventis Recherche & Développement450
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone - GETGOAL-PType II diabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005884-92-DESanofi-Aventis Recherche & Développement450